Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25654227 | 1.00 | CES2 (0.45) | CES2MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL23696048 | 0.91 | MEN1 (0.40) | CES2MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL22856475 | 0.91 | MEN1 (0.40) | CES2MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL23696339 | 0.91 | MEN1 (0.40) | CES2MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL10078895 | 0.89 | CES2 (0.40) | CES2ALDH1A1TDP1TSHR | |
| SCHEMBL13542695 | 0.89 | MEN1 (0.37) | CES2MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL23560429 | 0.83 | CES2 (0.42) | CES2MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL20932195 | 0.83 | CES2 (0.58) | CES2MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL22198415 | 0.83 | CES2 (0.58) | CES2MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL26279694 | 0.83 | CES2 (0.58) | CES2MEN1KMT2AALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| EP-4194457-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Leadingtac Pharmaceutical Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
| WO-2022147465-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, ITK, CRKL | CES2 885/4885MEN1 1064/4885KMT2A 1096/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CES2 1669/4885MEN1 4055/4885KMT2A 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.